Analysts Set Stryker Co. (NYSE:SYK) PT at $198.36

Shares of Stryker Co. (NYSE:SYK) have received an average recommendation of “Buy” from the twenty-two research firms that are covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $202.46.

Several equities analysts have issued reports on SYK shares. Svb Leerink reaffirmed an “outperform” rating on shares of Stryker in a report on Wednesday, July 10th. Barclays lifted their price target on shares of Zimmer Biomet from $113.00 to $117.00 and gave the stock an “underweight” rating in a report on Monday, April 15th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $68.00 price target on shares of Ionis Pharmaceuticals in a report on Wednesday, April 24th. Credit Suisse Group started coverage on shares of Merck & Co., Inc. in a report on Thursday, July 11th. They issued a “buy” rating and a $95.00 price target on the stock. Finally, ValuEngine raised shares of Yirendai from a “strong sell” rating to a “sell” rating in a report on Friday, May 3rd.

SYK stock traded down $0.09 during trading on Tuesday, hitting $205.40. 718,198 shares of the company’s stock traded hands, compared to its average volume of 1,265,764. The company has a market capitalization of $76.67 billion, a price-to-earnings ratio of 28.10, a P/E/G ratio of 2.50 and a beta of 0.87. The stock’s fifty day moving average price is $199.10. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.12 and a quick ratio of 1.30. Stryker has a 1 year low of $144.75 and a 1 year high of $210.85.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, April 23rd. The medical technology company reported $1.88 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.84 by $0.04. Stryker had a net margin of 25.38% and a return on equity of 26.72%. The company had revenue of $3.52 billion for the quarter, compared to analyst estimates of $3.51 billion. During the same period last year, the company posted $1.68 earnings per share. Stryker’s revenue was up 8.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Stryker will post 8.15 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th will be paid a dividend of $0.52 per share. The ex-dividend date is Thursday, June 27th. This represents a $2.08 annualized dividend and a dividend yield of 1.01%. Stryker’s payout ratio is currently 28.45%.

In related news, insider Timothy J. Scannell sold 4,666 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $186.71, for a total transaction of $871,188.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Louise Francesconi sold 2,679 shares of the business’s stock in a transaction on Thursday, April 25th. The shares were sold at an average price of $187.25, for a total transaction of $501,642.75. Following the transaction, the director now owns 15,598 shares of the company’s stock, valued at $2,920,725.50. The disclosure for this sale can be found here. Insiders have sold 16,711 shares of company stock valued at $3,184,233 over the last quarter. Insiders own 7.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Welch Group LLC raised its position in shares of Stryker by 1.5% in the first quarter. Welch Group LLC now owns 3,774 shares of the medical technology company’s stock worth $745,000 after acquiring an additional 54 shares during the period. Independence Bank of Kentucky raised its position in shares of Stryker by 4.9% in the first quarter. Independence Bank of Kentucky now owns 1,180 shares of the medical technology company’s stock worth $233,000 after acquiring an additional 55 shares during the period. Benedict Financial Advisors Inc. raised its position in shares of Stryker by 1.1% in the first quarter. Benedict Financial Advisors Inc. now owns 5,235 shares of the medical technology company’s stock worth $1,034,000 after acquiring an additional 57 shares during the period. Berman Capital Advisors LLC raised its position in shares of Stryker by 11.1% in the first quarter. Berman Capital Advisors LLC now owns 571 shares of the medical technology company’s stock worth $112,000 after acquiring an additional 57 shares during the period. Finally, 1ST Source Bank raised its position in shares of Stryker by 3.5% in the first quarter. 1ST Source Bank now owns 1,760 shares of the medical technology company’s stock worth $348,000 after acquiring an additional 60 shares during the period. Institutional investors own 73.57% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Story: What does a dividend yield signify to investors?

Analyst Recommendations for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.